[Form 4] ADMA Biologics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ADMA Biologics (ADMA) Form 4 highlights: Chief Operating Officer & SVP Compliance Kaitlin M. Kestenberg-Messina exercised 2,500 employee stock options on 07/30/2025 at an exercise price of $8.98 (code “M”).

To satisfy the exercise price and mandatory tax withholding, 1,208 shares were withheld by the issuer (code “F”), so no open-market sale occurred. Net 1,292 shares were added to the insider’s direct holdings.

Post-transaction ownership: 488,690 directly held common shares, consisting of 194,166 fully vested shares and 294,524 unvested RSUs from grants made between 2022-2025 that will vest quarterly over four-year schedules.

The 07/30/2015 option grant is now fully exercised and no derivative securities from this grant remain outstanding.

No other transactions, purchases, or sales were reported. Filing was signed 08/01/2025.

Insights

Securities Analyst

TL;DR: Routine option exercise; insider retains shares; negligible market impact.

The filing shows a standard expiration-date exercise of 2,500 options at $8.98, with share withholding for taxes. Because the shares were not sold in the market and the executive’s total beneficial ownership remains sizable at 488,690 shares, the transaction neither adds supply nor signals divestment. The sizeable unvested RSU inventory underscores continued alignment but is customary for senior management. Overall, the event is administrative, produces no cash flow for the company, and is unlikely to influence valuation or trading dynamics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kestenberg-Messina Kaitlin M.

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

5800 PARK OF COMMERCE BLVD. NW

(Street)

BOCA RATON FL 33487

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO and SVP, Compliance

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2025		M		2,500	A	$8.98	489,898	D
Common Stock	07/30/2025		F		1,208(1)	D	$18.59	488,690(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$8.98	07/30/2025		M			2,500	(4)	07/30/2025	Common Stock	2,500	$0	0	D

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements and payment by the Reporting Person of the option exercise price. This is not an open market sale of securities. This option was automatically exercised on the expiration date.

2. Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 15,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date;

3. (continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 194,166 shares of common stock directly owned by the reporting person, which includes the option exercise described in footnote 1 and prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

4. The option was granted on July 30, 2015 and is fully vested.

	/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ADMA shares did the insider acquire on 07/30/2025?

She exercised 2,500 options into common stock.

Did the COO sell any ADMA shares in the open market?

No. 1,208 shares were withheld for taxes; no open-market sale occurred.

What is the insider's total direct ADMA share ownership after the transaction?

She directly holds 488,690 common shares.

What was the exercise price of the options converted?

The options were exercised at $8.98 per share.

Are there remaining derivative securities from the 2015 option grant?

No. The 2015 grant is now fully exercised with zero options outstanding.